Fig. 5

Combination of Niraparib with PD-L1 blockade can enhance the proportion and function of T lymphocytes in vivo. A Flow cytometry analysis of CD3⁺CD4⁺T lymphocytes from the peripheral blood of mice treated with control (PBS, 100 μl), Niraparib (25 mg/kg, four times a week), PD-L1 blockade (10 mg/kg, twice a week), and the combination. B Flow cytometry analysis of CD3⁺CD8⁺T lymphocytes from the peripheral blood of the mice from the four treatment groups. C Flow cytometry analysis of CD4⁺IFN-γ⁺T lymphocytes from the peripheral blood of the mice from the four treatment groups. D Flow cytometry analysis of CD8⁺IFN-γ⁺T lymphocytes from the peripheral blood of the mice from the four treatment groups. E Quantification of data of lymphocytes with four different treatment groups. F Representative images of immunohistochemistry (IHC) staining for CD8 and IFN-γ staining from resected tumors with different treatments at day 52. Scale bar: 50 μm. G Quantification of lymphocytes and IFN-γ with different treatment groups. All experiments were repeated three times. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01